Covovax

SII's COVID-19 vaccine Covovax now available for children in India: Adar Poonawalla

SII's CEO Adar Poonawalla said the vaccine is in line with Prime Minister Narendra Modi's 'vision of providing yet another vaccine to protect our children'

Thailand gets India-made COVID vaccines under Quad initiative

This is the second consignment of vaccines delivered by India under the Quad vaccine partnership, after the inaugural supply to Cambodia on 12 April

SII hopeful of Covovax launch in India by Oct: A reader's guide to the new COVID-19 vaccine on the block

Covovax is Serum Institute of India's version of NVX-CoV2373, the protein-based COVID-19 vaccine developed by Novavax, headquartered in US. The vaccine is likely to be supplied at a price of Rs 1,114 per dose

Centre clears two new COVID-19 vaccines Covovax, Corbevax and Merck's COVID pill for EUA

With this approval, the number of COVID-19 vaccines which have received emergency use authorisation in the country has increased to eight.

Serum Institute-Novavax's anti-COVID vaccine gets emergency use listing from WHO

Adar Poonawalla, the CEO of Serum Institute of India (SII), hailed WHO's decision as "yet another milestone" in the fight against COVID-19.

Govt panel recommends against allowing SII to conduct trial of Covovax on children; all you need to know

The expert group responsible for assessing the merits of SII's proposal has noted that the vaccine has not been approved in any country and the trial on adult population in India also began only in March

SII manufacturing first batch of Novavax's COVID-19 vaccine Covovax, says Adar Poonawalla

In March, Poonawalla had said that the clinical trials of the Covovax vaccine have begun in India and the company hopes to launch it by September this year

Novavax vaccine leaves Covishield, Covaxin way behind with 90.4% overall efficacy

Likely to be priced at Rs 1,114 per dose in India, Novavax vaccine will be a two-dose jab like the other vaccines

Serum institute begins Covovax clinical trials in India, vaccine may launch by September

The development and commercialisation pact between Novavax and SII excludes major upper-middle and high-income countries as they retain the rights

Pune's Serum Institute of India applies for permission to start trials of 'Covovax' vaccine

The company is aiming to launch the vaccine being produced in collaboration with American vaccine development company Novavax by June 2021, SII CEO Adar Poonawalla said